Novo Nordisk to present new data from key diabetes and obesity trials at the 60th Annual Meeting of the European Association for the Study of Diabetes

New pooled analysis published in The Lancet demonstrated reduced risk of combined CV death or worsening heart failure with semaglutide

Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to USD 19.3 billion in the first six months of 2024